Last week, three insiders from Maiden Holdings, Ltd. (MHLD) filed Form 4s disclosing the purchase of 380,000 shares at an average price of $0.78 per share. An interesting cluster of buying. But here's what's astonishing -- just seven months earlier the stock traded at $8.75.
The Lottery Ticket Stocks Q2 2019 portfolio was down 6.72% for the quarter, tracking the Russell 2000 Index lower. However, the portfolio of top hedge funds' most speculative holdings, rebalanced quarterly based on 13F filings, was up 35.65% year-to date as of August 15.
Perceptive Advisors' Neptune Wellness Solutions (NEPT) position increased by 50% during the 3rd quarter of 2019, to 4.5 million shares. The stake represents 14.53% of the Cannabis extraction company's outstanding shares. NEPT was Perceptive Advisors' #20 position at Q3 close. The increase in Perceptive'...
Billionaire Mori Arkin filed a 13D on Aclaris Therapeutics (ACRS), a development stage microcap biotech company with a promising treatment for common warts. Arkin bought the shares through his personal partnership, "The 1999 Company." In the activist filing he disclosed the following trades: Purchase/SaleSharesPriceDate Running ...
Whether they’re called penny stocks, micro-caps, OTC stocks or “lottery tickets,” low-priced, illiquid stocks of small companies have a bad reputation with many investors. Unquestionably micro-cap stocks can be illiquid, risky and highly speculative. Nonetheless, Hedge Funds can and do hold lots of micro-caps.
Replicating Baker Brothers holdings, using 13F filings submitted quarterly by the life sciences hedge fund, has been an awesome strategy over the years. But by focusing on the smaller stocks owned by the fund, returns were even better. Baker Bros Advisors LP, with $17.33...
A three day (dead cat?) bounce propelled the S&P 500 over 13% higher last week, rescuing stocks, at least temporarily, from the worst stretch of performance since the dark days of 1929. During the Coronavirus crash over the last several weeks, stocks were liquidated indiscriminately, as investors...
Obscure stocks -- publicly traded, unknown, hidden companies with little or even no analyst coverage -- may not seem like good investments. Seriously, who wants to invest in a stock no one has ever heard of? Some of the top hedge fund managers in the world, that's...
Twenty-two minutes after regular market hours closed on July 2, an Orbimed Advisors Form 4 relating to Corvus Pharmaceuticals Inc (CRVS) was posted on the SEC's website. The hedge fund, a 10%+ holder and insider in CRVS, disclosed that between June 27 and July 1 it...